Breast Cancer Trial, Recruiting NCT04158843 Sponsor: xuexin he Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04158843
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to participate
  • Women between 18 and 75 years old
  • People who have been diagnosed with breast cancer confirmed by a tissue test, and who have had a full surgical removal of the breast (radical mastectomy)
  • People whose breast cancer has spread in a limited way (called oligometastasis) to the upper arm bone (humerus) or breastbone (sternum) on the same side as the original cancer, with no imaging evidence of cancer spread anywhere else
  • People who have recovered well from side effects of any previous treatments, with only mild or no lingering effects
  • People whose HIV test result from a central laboratory is negative before entering the trial
  • People whose liver function blood test results (ALT, AST, alkaline phosphatase, GGT, and bilirubin) are within acceptable ranges before the trial begins
  • People whose blood protein (albumin) level is at or above a minimum acceptable level
  • People whose kidney function blood test (creatinine) is within an acceptable range
  • People whose blood count results — including white blood cells, neutrophils, platelets, and haemoglobin — are all within acceptable minimum ranges
  • People who are reasonably physically active and able to carry out daily activities, as measured by a standard medical scoring system (ECOG score of 0 to 2)
  • Women who could become pregnant and who are using effective contraception

Who may not be able to join:

  • People who have not had a full surgical removal of the primary breast tumour
  • People whose spread of cancer cannot be treated with surgery or radiotherapy
  • People whose cancer has spread to any site other than the upper arm bone or breastbone on the same side as the original cancer
  • People who have more than one area where the cancer has spread
  • People who have, or have had within the past five years, another type of cancer (with some exceptions for very early-stage cancers such as early cervical carcinoma in situ, skin basal cell carcinoma, or early-stage papillary thyroid carcinoma — confirm with trial site)
  • People with an active HIV infection at the time of starting the trial
  • People who have taken part in another clinical trial within the 30 days before joining this trial
  • People who are known to be unable to tolerate surgery on the humerus or sternum, or unable to tolerate radical radiotherapy
  • People who are pregnant or breastfeeding
  • People with a serious ongoing illness, such as a significant heart, lung, or kidney condition
  • People who are not legally able to make decisions for themselves
  • People who, in the opinion of the trial investigator, may not be able to complete the study or sign the consent form due to a medical or mental health condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaobo Yan, MD, The Second Affiliated Hospital of Zhejiang University School of Medicidne

Phone: +86-18329139569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
xuexin he
Registry
ClinicalTrials.gov
Start date
9 May 2020
Est. completion
31 December 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov